ストックスクリーナーアプリを入手
0.7201
1.63%
-0.0119
アフターアワーズ：
.73
0.0099
+1.37%
前日終値:
$0.732
開ける：
$0.746601
24時間の取引高:
41,809
Relative Volume:
0.03
時価総額：
$4.59M
収益：
-
当期純損益:
$-11.27M
株価収益率:
-0.0336
EPS:
-21.4132
ネットキャッシュフロー:
$-9.40M
1週間 パフォーマンス:
-3.21%
1か月 パフォーマンス:
-4.41%
6か月 パフォーマンス:
-36.18%
1年 パフォーマンス:
-80.11%
1日の値動き範囲:
$0.7201
$0.7466
1週間の範囲:
$0.7201
$0.76
52週間の値動き範囲:
$0.69
$5.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
名前
Dermata Therapeutics Inc
セクター
電話
(858)-223-0882
住所
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
DRMA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
0.7201 | 4.75M | 0 | -11.27M | -9.40M | -21.41 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Dermata Therapeutics Inc (DRMA) 最新ニュース
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World
Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World
Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World
Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria
Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria
Dermata gears up for phase 3 trial of XYNGARI - Investing.com
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks
Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com
Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com
Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus
Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks
Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus
DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus
Dermata Reports Positive Phase 3 Trial Results - TipRanks
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
Dermata Therapeutics stock hits 52-week low at $0.7 - Investing.com Australia
Dermata reports early success in acne treatment with XYNGARI By Investing.com - Investing.com South Africa
Dermata Therapeutics (DRMA) Reports Promising Phase 3 Trial Resu - GuruFocus
Dermata reports early success in acne treatment with XYNGARI - Investing.com
First-Ever Weekly Acne Treatment XYNGARI Achieves Major Phase 3 Success - Stock Titan
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Up 307.9% in March - Defense World
Dermata Therapeutics stock hits 52-week low at $0.79 By Investing.com - Investing.com Canada
Dermata Therapeutics stock hits 52-week low at $0.79 - Investing.com
Acne Vulgaris Market to Reach New Heights in Growth by 2034, - openPR.com
Dermata Therapeutics stock hits 52-week low at $1 - Investing.com
Dermata (DRMA) Initiates Warrant Exercise to Raise $6.2 Million - GuruFocus
Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results - Investorideas.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Dermata Therapeutics (NASDAQ:DRMA) Shares Up 5.2% – Here’s What Happened - Defense World
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance
Dermata Raises Fresh $6.2M Capital: New Funding Fuels Clinical Pipeline Advancement - Stock Titan
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne - Benzinga
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Pre-Market Momentum: Dermata Therapeutics (DRMA) Sees Sharp Gains - Stocks Telegraph
XYNGARI shows promise in Phase 3 acne trial By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results By Investing.com - Investing.com South Africa
Dermata shares rise on positive acne treatment trial results - Investing.com
Dermata Therapeutics Inc (DRMA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):